Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LTRN
stocks logo

LTRN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.540
-0%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Lantern Pharma Inc. (LTRN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -12.53%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-12.53%
In Past 3 Month
Wall Street analysts forecast LTRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTRN is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast LTRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTRN is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.770
sliders
Low
25.00
Averages
25.00
High
25.00
Current: 3.770
sliders
Low
25.00
Averages
25.00
High
25.00
Lake Street
Chad Messer
Strong Buy
Initiates
$25
2025-04-02
Reason
Lake Street
Chad Messer
Price Target
$25
2025-04-02
Initiates
Strong Buy
Reason
Lake Street initiated coverage of Lantern Pharma with a Buy rating and $25 price target. Lantern's Response Algorithm for Drug Positioning and Rescue, or RADR, platform consists of a suite of AI modules designed to help advance cancer drug development, the analyst tells investors. Unlike many biotech AI platform companies, Lantern is monetizing RADR through advancement of its own pipeline of four clinical, plus additional preclinical, stage molecules, though they also engage in collaborations with partners, adds the analyst, who notes that lead clinical program LP-300 targets a unique set of lung cancer patients who never smoked.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lantern Pharma Inc (LTRN.O) is -2.41, compared to its 5-year average forward P/E of -4.39. For a more detailed relative valuation and DCF analysis to assess Lantern Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.39
Current PE
-2.41
Overvalued PE
-0.53
Undervalued PE
-8.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.73
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.51
Undervalued EV/EBITDA
-2.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LTRN News & Events

Events Timeline

(ET)
2025-12-03
09:00:00
Lantern Pharma Completes LP-184 Trial, 63 Patients Show Promising Efficacy
select
2025-11-07 (ET)
2025-11-07
09:08:43
Lantern Pharma Partners with New to The Street for Media Initiative
select
2025-10-28 (ET)
2025-10-28
08:57:53
Lantern Pharma unveils clinical findings from LP-284
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03NASDAQ.COM
PinnedLantern Pharma Announces Encouraging Phase 1a Results for LP-184 in Advanced Solid Tumors

  • Clinical Study Results: Lantern Pharma's Phase 1a dose-escalation study of LP-184 demonstrated promising disease control in patients with advanced solid tumors and DNA damage repair deficiencies, meeting all safety and tolerability endpoints.

  • Future Plans: The company intends to progress LP-184 into multiple Phase 1b/2 trials following the successful outcomes of the initial study.

[object Object]
Preview
9.0
10-28Newsfilter
Lantern Pharma Showcases LP-284 Clinical Findings at 25th LL&M Congress, Emphasizing Full Response in DLBCL Patient with Limited Treatment Options and Its Promise for Advanced B-Cell Cancers.

  • Clinical Success of LP-284: LP-284, an AI-driven drug candidate, achieved a complete metabolic response in a patient with aggressive B-cell lymphoma after just two cycles, validating its synthetic lethal mechanism and addressing treatment gaps for patients who have failed CAR-T and bispecific therapies.

  • Strategic Partnership Potential: The drug's profile presents significant partnership opportunities for biopharmaceutical companies, particularly due to its novel mechanism that overcomes resistance to current therapies and demonstrates preclinical synergy with existing FDA-approved agents like rituximab.

  • Market Need and Economic Impact: With approximately 200,000 new DLBCL cases diagnosed annually and high post-relapse treatment costs, LP-284's off-the-shelf administration could alleviate both clinical and economic burdens in the post-immunotherapy setting.

  • Ongoing Development and Future Prospects: Lantern Pharma is advancing LP-284 through a Phase 1 trial while exploring combination therapy opportunities, with plans for further clinical assessments and potential expansion into autoimmune and inflammatory conditions.

[object Object]
Preview
1.0
10-24Newsfilter
Lantern Pharma to Showcase at ThinkEquity Conference in New York City on October 30, 2025

  • Company Presentation: Lantern Pharma Inc. will present at the ThinkEquity Conference on October 30, 2025, at 11:30 a.m. ET in New York, NY, with opportunities for one-on-one meetings available throughout the event.

  • AI-Driven Drug Development: The company utilizes its proprietary AI platform, RADR®, to enhance oncology drug discovery and development, aiming to address significant challenges in the field and potentially impacting over $15 billion in market potential.

  • Clinical Programs: Lantern Pharma is advancing multiple clinical programs, including a Phase 2 program and several Phase 1 trials, targeting various cancer types with the goal of providing innovative therapies to patients.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance and drug development plans, highlighting potential risks and uncertainties that could affect outcomes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lantern Pharma Inc (LTRN) stock price today?

The current price of LTRN is 3.77 USD — it has increased 6.5 % in the last trading day.

arrow icon

What is Lantern Pharma Inc (LTRN)'s business?

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

arrow icon

What is the price predicton of LTRN Stock?

Wall Street analysts forecast LTRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTRN is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lantern Pharma Inc (LTRN)'s revenue for the last quarter?

Lantern Pharma Inc revenue for the last quarter amounts to -4.35M USD, decreased -16.02 % YoY.

arrow icon

What is Lantern Pharma Inc (LTRN)'s earnings per share (EPS) for the last quarter?

Lantern Pharma Inc. EPS for the last quarter amounts to -4572535.00 USD, decreased -18.13 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lantern Pharma Inc (LTRN)'s fundamentals?

The market is revising No Change the revenue expectations for Lantern Pharma Inc. (LTRN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -12.53%.
arrow icon

How many employees does Lantern Pharma Inc (LTRN). have?

Lantern Pharma Inc (LTRN) has 24 emplpoyees as of December 05 2025.

arrow icon

What is Lantern Pharma Inc (LTRN) market cap?

Today LTRN has the market capitalization of 41.94M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free